Sucampo Pharma (SCMP) Tops Q4 EPS by 20c, Names CFO

Sucampo Pharma (NASDAQ: SCMP) reported Q4 EPS of $0.68, $0.20 better than the analyst estimate of $0.48. Revenue for the quarter came in at $73 million versus the consensus estimate of $66 million.

Sucampo today reiterated its guidance for the full year ending December 31, 2017.

Additionally, today Sucampo announced two updates to its executive management team. Andrew Smith, Chief Financial Officer, will be leaving Sucampo to move back to Europe with his family to pursue professional opportunities there. He will remain in his CFO role through March 20 and will thereafter assist in the transition of his responsibilities. Peter Pfreundschuh, CPA will become Sucampo’s new Chief Financial Officer, effective on March 20. Also, effective March 20, Jones “Woody” Bryan, Ph.D. will become Sucampo’s new Senior Vice President of Business Development and Licensing.

For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.

You May Also Be Interested In

• KLX Energy narrows Q3 2026 revenue guidance, completes rights offering
• Bernstein sees downside risk to Apple's December quarter results
• Darden Restaurants (DRI) Reports In-Line Q1 EPS, Misses on Revenue; Offers FY27 EPS Guidance